History

«JSC «PE «Obolenskoe» is established at the base of State Research Center for Applied Microbiology and Biotechnology, Obolensk, the Serpukhov District, the Moscow Region.

Reconstruction of the enterprise’s premises and launch of new production lines. As a result, a twofold increase in production volume.

«JSC «PE «Obolenskoe» underwent two external audits confirming the compliance of its pharmaceuticals’ quality with the QMS (ISO) and the requirements of international GMP standards.

The enterprise became a part of Alvansa Group since 2013; Gazprombank and the UFG Private Equity Investment Fund are its shareholders.

Alvansa Group acquired Segmenta Pharmaceuticals, LLC, thereby expanding its product line.

The company purchased Urdoksa^® and Novobismol^® brands from the pharmaceutical company Pharmproject, JSC (St. Petersburg).

Start of investment program to modernize and expand the enterprise’s production facilities with the aim of increasing production volume of pharmaceutical products produced, as well as new products. Development of some sites of partner companies for the production of pharmaceuticals by «JSC «PE «Obolenskoe».

The company began building new production facilities.

According to DSM data for 2016, sales of Venarus^® in packages have reached 61% in the last 5 years, bringing the product into second place in its category.

December 28, 2018 - Sistema, a public Russian diversified holding company, acquired a stake in «JSC «PE «Obolenskoe». The package was acquired jointly with VTB Bank and OBL Pharm management from Alvansa Ltd, the main shareholders of which are Gazprombank and UFG Private Equity.

On February 7, the grand opening of a new production site of «JSC «PE «Obolenskoe» took place.